| Name | Title | Contact Details |
|---|
Hustle Nation Podcast covers everything from leadership to finances, culture, sales, coaching, and personal branding, and most importantly we discuss topics that deliver results. We bring the hustle from the people who have it to the people who need it. We do this by interviewing highly successful leaders, entrepreneurs, and coaches. Our guests share their stories of adversity and success along with their tactics and strategies for crushing success. Its our personal goal to turn our listeners into Hustle Nation advocates and advocates into success stories. So stop reading and start listening.
Big Brand Tire & Service is a tire and automotive service retailer founded in 1969 in Moorpark, California. With over 215 locations across six states, primarily in the Southwest US, it ranks among the top 10 largest tire dealerships in the country. The company was acquired by Percheron Capital in 2021, which has fueled its rapid expansion through multiple acquisitions. The company specializes in a wide range of tire and automotive maintenance services. It offers major tire brands such as Bridgestone, Michelin, and Goodyear, along with services including tire sales, wheel alignment, oil changes, brake inspections, and full-service auto repair. Big Brand Tire & Service emphasizes customer satisfaction and aims to be a reliable one-stop shop for tire and auto repair needs. The company is committed to maintaining its locally owned heritage while focusing on long-term growth and community support.
With a history spanning more than 145 years, Columbus McKinnon has become a global leader in intelligent motion solutions. Our high-quality brands, such as CM®, STAHL CraneSystems®, Yale®, Magnetek®, Coffing® Hoists, Dorner®, and Duff-Norton®, work together to move the world forward and improve lives. Whether its increasing safety or improving productivity, our intelligent motion technology is hard at work worldwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.